Probiotics for Dog Anxiety: Gut-Brain Axis Evidence Review

The gut-brain axis in dogs

The gastrointestinal microbiome is recognized as a metabolically active organ linked to the central nervous system (Pilla et al., 2020; PMCID: PMC6971114). This bidirectional pathway — the gut-brain axis — operates through the enteric nervous system, the vagus nerve, circulating metabolites, and immune signaling.

Intestinal microbiota can produce neuroactive molecules including γ-aminobutyric acid (GABA), serotonin, melatonin, histamine, dopamine, and norepinephrine (Ambrosini et al., 2019; PMCID: PMC6591269). Bacterial metabolites such as short-chain fatty acids (SCFAs) — acetic acid, butyric acid, and propionic acid — can target the enteric nervous system. They have been associated with downstream effects on learning and memory, though the full mechanistic chain has not been tested in a single canine study (Ambrosini et al., 2019; PMCID: PMC6591269).

In human research, gut-brain axis disruptions have been linked to depression, anxiety, and autism, as well as neurodegenerative conditions (Ambrosini et al., 2019; PMCID: PMC6591269). These links are biologically plausible in dogs given shared mammalian axis architecture, but direct canine experimental evidence remains limited.

The dog gut microbiome is more similar to the human microbiome in composition and function than rodent models are (Ambrosini et al., 2019; PMCID: PMC6591269). This structural overlap makes dogs a relevant species for gut-brain research that may translate across veterinary and human medicine.

Canine gut microbiome composition and stability

The five dominant bacterial phyla in the canine gastrointestinal tract are Firmicutes, Fusobacteria, Bacteroidetes, Proteobacteria, and Actinobacteria (Pilla et al., 2020; PMCID: PMC6971114). These phyla are similar to those found in humans. The GI microbiome supports nutrient breakdown and produces metabolites including SCFAs, secondary bile acids, and vitamins (Wernimont et al., 2020; PMCID: PMC7329990).

The dog gut microbiome is more similar to the human microbiome than those of pigs or mice (Coelho et al., 2018; PMCID: PMC5907387). In a study of 63 dogs, canine gut gene sequences mapped to the human gut gene catalog at 63%, compared to 32.9% for pigs and 19.9% for mice (Coelho et al., 2018; PMCID: PMC5907387).

The gut microbiome is generally stable in adult healthy dogs. Age, diet, and other factors can alter it, though these alterations are smaller than those seen in diseased animals (Pilla et al., 2020; PMCID: PMC6971114). Diet has a large and reproducible effect on the microbiome, independent of breed or sex (Coelho et al., 2018; PMCID: PMC5907387). In a crossover study of 8 dogs, a raw meat-based diet was linked to higher Shannon biodiversity than a commercial extruded diet, though the small sample limits generalizability (Sandri et al., 2016; PMCID: PMC5331737). Breed, age, and living environment also contribute to variation between individual dogs (Wernimont et al., 2020; PMCID: PMC7329990).

A study of 46 cats and 192 dogs found that cats had higher gut microbiome alpha diversity than dogs (Wernimont et al., 2020; PMCID: PMC7329990). The greater variation among dogs may reflect a more varied, omnivorous diet compared to feline carnivory (Wernimont et al., 2020; PMCID: PMC7329990).

Dysbiosis and behavioral health

Gut dysbiosis occurs when microbiota alterations produce functional changes in the microbial transcriptome, proteome, or metabolome (Pilla et al., 2020; PMCID: PMC6971114). In dogs, both chronic and acute intestinal inflammation are associated with shifts in microbiota composition (Pilla et al., 2020; PMCID: PMC6971114). Antibiotic use causes a rapid decrease in microbial richness, diversity, and evenness (Pilla et al., 2020; PMCID: PMC6971114).

Metabolites commonly affected in canine dysbiosis include short-chain fatty acids and amino acids such as tryptophan and its catabolites (Pilla et al., 2020; PMCID: PMC6971114). Tryptophan is a serotonin precursor. Disruption of its gut metabolism is of interest in behavioral health research, though causal links between gut tryptophan pathways and canine behavioral states have not been shown in controlled canine studies.

Dietary components may influence GI disease, allergies, weight management, and several other conditions through microbiome changes, though causal relationships remain to be established (Wernimont et al., 2020; PMCID: PMC7329990). Microbiome disturbances may worsen illness, while nutritional interventions that support microbiome function may improve health in cats and dogs (Wernimont et al., 2020; PMCID: PMC7329990).

In humans, gut microbiome alterations have been reported in neurodegenerative diseases including Alzheimer's and Parkinson's (Ambrosini et al., 2019; PMCID: PMC6591269). Whether analogous gut-behavior linkages operate in dogs is an open research question. Direct canine evidence is primarily from gastrointestinal disease contexts rather than behavioral or mood-related conditions.

Dietary and probiotic interventions

Probiotics are typically unable to permanently colonize the gut. Instead, the metabolites they produce in transit through the gastrointestinal tract may modify microbiome composition and reduce clinical signs (Pilla et al., 2020; PMCID: PMC6971114). Metabolite production — not stable colonization — is the proposed mechanism of probiotic benefit in dogs.

Probiotics and prebiotics have been reported to possess gut-microbiota-balancing properties in narrative reviews (Nicotra et al., 2025; PMCID: PMC12568156). These nutraceuticals may help prevent or manage behavioral disturbances, though specific compounds, conditions, and evidence strength are not detailed in the cited passage (Nicotra et al., 2025; PMCID: PMC12568156). Nutrition has also been proposed to influence the gut-brain axis, with potential effects on behavior, cognition, and stress resilience (Nicotra et al., 2025; PMCID: PMC12568156).

A case series (n=24) by Cerbo et al. (2017; PMCID: PMC5407696) studied dogs with behavioral disturbances primarily attributed to generalized anxiety receiving a nutraceutical diet combined with counterconditioning and desensitization behavioral therapy for 10 days. Dogs in this uncontrolled case series showed statistically significant improvement in time spent active (p < 0.01) and at rest (p < 0.05), as well as overall significant improvement in clinical and behavioral symptoms (Cerbo et al., 2017; PMCID: PMC5407696). The absence of a control group means the individual contribution of the diet cannot be isolated from the behavioral therapy component.

One narrative review of integrative treatment approaches for canine separation anxiety listed Lactiplantibacillus plantarum PS128 as one of several integrative modalities discussed alongside behavioral training and pharmacological options, though evidence quality for this specific strain in canine anxiety contexts was not characterized in the cited passage (Andena et al., 2023; DOI: 10.31533/pubvet.v17n01a1330).

Fecal microbiota transplantation (FMT) has been proposed as a potentially promising tool to aid recovery from dysbiosis in dogs, though further studies are needed to evaluate its potential and limitations (Pilla et al., 2020; PMCID: PMC6971114). Clinical recovery from gastrointestinal issues does not necessarily correlate with recovery of the gut microbiome's composition, and the long-term consequences of lingering microbiome alterations are not yet established (Pilla et al., 2020; PMCID: PMC6971114).

Evidence gaps and limitations

The evidence connecting probiotics to canine anxiety outcomes is primarily narrative reviews, mechanistic hypotheses from human and rodent research, and a small number of uncontrolled canine studies. Several gaps limit clinical interpretation.

Randomized controlled trials in dogs examining probiotic supplementation for behavioral or anxiety outcomes are limited. Probiotic psychobiotics — strains with proposed mental-health effects — are an early-stage field in human medicine. Most rigorous trials focus on depression and stress in humans rather than canine behavioral medicine. Direct canine experimental evidence for gut-brain axis effects on anxiety behaviors is sparse compared to gastrointestinal and immune endpoints.

Strain specificity is an important unresolved variable. Different Lactobacillus and Bifidobacterium strains have distinct metabolic profiles. The behavioral relevance of any probiotic depends on strain selection, dose, and formulation — variables rarely controlled in canine studies. Mechanisms such as serotonin precursor production from gut tryptophan have been characterized primarily in rodent and in vitro models, with limited canine-specific validation.

Microbiome composition is correlated with overall health in dogs (Pilla et al., 2020; PMCID: PMC6971114). Correlation does not establish whether microbiome changes cause behavioral outcomes, result from them, or share an upstream driver. Nutritional interventions targeting the microbiome likely need to be tailored for specific conditions, since patterns observed in healthy and diseased dogs differ substantially (Wernimont et al., 2020; PMCID: PMC7329990).

Frequently asked questions